AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

RecruitingNAAges 14 Days - 90 DaysAllChildren's Hospital of Fudan University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients whose age of operation is 14-90 d. Sex and race are not restricted; * Patients who are born with gestational age older than 36 weeks; * Patients whose body weight before operation \> 2 kg; * Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University; * The type-III BA diagnosis is based on cholangiography or operation; * Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported; * Patients who are not allergic to postoperative medications; * Patients who haven't accepted other antibiotic or probiotic therapy. Exclusion Criteria: * Patients with cholestasis of non-BA disease; * Patients who have undergone KP at other institutions; * Patients whose pathohistological diagnosis is in doubt; * Patients who undergo liver transplantation immediately after KP; * Patients with other liver diseases or severe complications (e.g., severe pulmonary hypertension, renal failure, intracranial hemorrhage, etc.) requiring surgical intervention or other medical therapy; * Patients with severe cardiac, renal, or central nerve system malformations (e.g., tetralogy of Fallot, transposition of the great arteries, cerebral dysplasia, etc.) and have poor prognosis; * Patients judged by the researchers that they can not comply with the study requirements.
๐Ÿ’Š

What it tests

  • Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem
  • Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
๐Ÿ“

Where

1 site
Children's Hospital of Fudan University
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy